Skip to main content
SK Bioscience Co.,Ltd logo

SK Bioscience Co.,Ltd — Investor Relations & Filings

Ticker · 302440 ISIN · KR7302440003 KO Manufacturing
Open in API
Filings indexed 383 across all filing types
Latest filing 2022-06-29 Regulatory Filings
Country KR South Korea
Listing KO 302440

About SK Bioscience Co.,Ltd

https://www.skbioscience.com/

SK Bioscience is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines and biological products. Spun off from SK Chemicals in 2018, the company develops its own pipeline of vaccines, including cell-culture-based influenza vaccines and a COVID-19 vaccine, utilizing its established R&D and production platforms. In addition to its proprietary products, SK Bioscience provides global Contract Development and Manufacturing Organization (CDMO) services, offering end-to-end support from process development to large-scale commercial manufacturing for international partners. The company is dedicated to promoting public health by providing innovative preventative solutions to address global health challenges.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(COVID-19 백신 스카이코비원(GBP510)의 국내 품목허가 획득)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from SK Bioscience regarding the approval of their COVID-19 vaccine, SKYCovione, by the Ministry of Food and Drug Safety (MFDS). It is a 'Major Management Matter' (투자판단 관련 주요경영사항) filing, which is a standard regulatory disclosure in the Korean market (KIND system). Since it does not fit into specific categories like financial reports, dividends, or director dealings, and serves as a general regulatory announcement of a material corporate event, it is classified as a Regulatory Filing (RNS).
2022-06-29 Korean
기업지배구조보고서공시
Governance Information Classification · 1% confidence The document is a short announcement (1040 characters) titled 'Corporate Governance Report Disclosure' which explicitly states that the detailed report is attached ('상세한 내용은 첨부된... 참조하시기 바랍니다'). According to the 'Menu vs Meal' rule, an announcement of a report that directs the reader to an attachment is classified as a Report Publication Announcement (RPA).
2022-05-31 Korean
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
Major Shareholding Notification Classification · 1% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) for SK Bioscience, which is a mandatory regulatory filing in South Korea under the Fair Trade Commission's regulations for large business groups. It contains detailed information on company structure, financial status, board composition, and inter-company transactions. Since it is a formal regulatory disclosure required by law and does not fit into specific categories like 10-K (which is a US-specific term) or Earnings Release, it is classified as a Regulatory Filing (RNS).
2022-05-31 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is specifically used to report insider transactions (share disposals/acquisitions) by company directors or major shareholders. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2022-05-25 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (specifically a sale of shares) by an executive (Cho Tae-jun) of SK Bioscience. This type of filing is a standard disclosure for insider trading/director dealings in the Korean market, which maps directly to the 'Director's Dealing' category.
2022-05-25 Korean
투자판단관련주요경영사항(COVID-19 백신 GBP510의 부스터샷 태국 제3상 임상시험계획(IND) 신청)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from SK Bioscience regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the submission of an Investigational New Drug (IND) application for a Phase 3 clinical trial of a COVID-19 vaccine booster. This type of disclosure is a standard regulatory announcement in the Korean market (DART system) for material corporate events. Since it does not fit into specific categories like M&A, dividends, or financial reports, it falls under the 'Regulatory Filings' category.
2022-05-23 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.